Focus Areas

Mucosis’ research efforts are centered around the development of vaccines that are administered to the mucosal layers e.g. those of the nose and mouth, with the intent to raise both a systemic and a strong local immune reaction that efficiently prevents invasion of pathogens into the body. To achieve this, we have developed the unique technology Mimopath® that we use to re-formulate existing vaccines such that they, for example, can be given to humans with a simple nose spay instead of an intramuscular injection. Our current focus is on the development of vaccines that prevent diseases caused by respiratory tract pathogens. In addition, we employ our technology to develop new vaccines that address other unmet medical needs.

Read more >

versatile vaccine

07.11.16 Mucosis Initiates First-in-Human Study of SynGEM®, a Needle-Free Nasal Spray RSV Vaccine
more >

24.03.16 Mucosis to Present at World Vaccines Congress 2016
more >

20.01.16 Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London
more >

19.05.15 Mucosis to Present Data on Intranasal RSV Vaccine SynGEM® at Modern Vaccines Adjuvants & Delivery Systems 2015
more >

23.03.15 Mucosis to Present on Intranasal Respiratory Syncytial Virus Vaccine Candidate SynGEM® at BioCapital Europe
more >

10.11.14 Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium
more >

20.10.14 Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference
more >